Ninlaro (ixazomib) / Takeda  >>  Phase 4
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ninlaro (ixazomib) / Takeda
NCT03416374: A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

Completed
4
45
Japan
Ixazomib, Bortezomib, Carfilzomib, Lenalidomide, Dexamethasone
Takeda
Relapsed and/or Refractory Multiple Myeloma
05/21
05/21
US MM-6, NCT03173092: A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

Active, not recruiting
4
141
US
Ixazomib, NINLARO, MLN9708, Lenalidomide, Dexamethasone
Takeda
Multiple Myeloma
11/26
11/26
US MM-7, NCT05183139: A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Withdrawn
4
0
NA
Ixazomib, NINLARO, Pomalidomide, POMALYST, Lenalidomide, REVLIMID, Dexamethasone
Takeda
Multiple Myeloma
12/26
12/26

Download Options